John L. Marshall, MD
The importance of molecular profiling in the establishment of a treatment plan for patients with colorectal cancer (CRC) continues to grow. For example, the latest anticancer therapies approved by the FDA for use in CRC—larotrectinib (Vitrakvi) and the checkpoint inhibitor combination of nivolumab (Opdivo)/ipilimumab (Yervoy)—are indicated for patients with specific molecular markers.
With multiple biomarker-directed clinical trials for metastatic CRC (mCRC) expected to produce data within the next few years, experts in gastrointestinal (GI) oncology who took part in a recent OncLive Peer Exchange®
program recommended that clinicians become more proactive about incorporating genomic and immune markers into their decision making.
The experts joined moderator John L. Marshall, MD, for a wideranging discussion on how findings from recent studies, including data presented at the 2019 Gastrointestinal Cancers Symposium, are refining the way clinicians manage advanced CRC, particularly in the perioperative and metastatic settings.
... to read the full story